jjogastroenterology.org

Japanese Journal of Gastroenterology

ISSN 2832-4870

DIRECTIVE PUBLICATIONS

Review Article

Evaluating Rifaximin-Metronidazole Regimens for Helicobacter pylori Eradication: Current Evidence and Future Perspectives.

Dr. Arif A. Faruqui

Affiliations:

MD, MBBS Clinical Pharmacologist Department of Pharmacology 504-A, Rizvi Mahal CHS Opp. K. B. Bhabha Hospital Bandra West, Mumbai-400050 Maharashtra, India.

Abstract

Helicobacter pylori (H. pylori) infection remains a global health challenge, with rising antibiotic resistance compromising the efficacy of standard eradication regimens. The rifaximin-metronidazole combination has emerged as a promising alternative, offering a dual mechanism of action, low resistance potential, and favorable safety profile. Rifaximin, a non-absorbable rifamycin derivative, exhibits high intraluminal concentrations and broad-spectrum activity against *H. pylori*, while metronidazole provides systemic coverage against deeper mucosal bacteria. In vitro studies have demonstrated rifaximin's consistent activity against *H. pylori*, including clarithromycin- and metronidazole-resistant strains. Clinical trials evaluating rifaximin-based regimens have reported moderate eradication rates (55.3–85.4%), with the rifaximin-metronidazole combination showing 60% success as a dual therapy. While falling short of the ideal 90% eradication rate, this combination offers advantages in penicillin-allergic patients, those intolerant to bismuth or macrolides, and in rescue therapy settings. The absence of large-scale randomized controlled trials and standardized protocols remains a limitation. Future research should focus on optimizing formulations, dosing, and treatment duration to enhance efficacy. Targeted studies in niche populations, such as those with prior treatment failures or gastrointestinal comorbidities, can further define the role of rifaximin-metronidazole in personalized treatment strategies. With its unique pharmacological benefits and potential for overcoming resistance barriers, the rifaximin-metronidazole combination warrants further investigation as a valuable addition to the *H. pylori* eradication arsenal.

Keywords: *Helicobacter pylori*, Rifaximin, Metronidazole, Antibiotic resistance, Eradication therapy.

INTRODUCTION

Helicobacter pylori (H.pylori) is a gram-negative, microaerophilic bacterium that colonizes the human gastric mucosa and is a major etiological agent responsible for several gastrointestinal diseases (1). Discovered by Warren and Marshall in 1982, the identification of *H. pylori* radically changed the understanding and management of peptic ulcer disease (2). It is now well-established that *H. pylori* infection is implicated in the pathogenesis of chronic gastritis, gastric and duodenal ulcers, mucosa-associated lymphoid tissue lymphoma, and gastric adenocarcinoma. Owing to its global prevalence and associated disease burden, *H. pylori* has been classified as a Class I carcinogen by the World Health Organization (3).

Approximately 50% of the global population is infected with *H. pylori*, with significantly higher prevalence in developing countries due to factors such as poor sanitation, overcrowding, and limited access to healthcare (3). The bacterium is typically acquired during childhood and, if untreated, can persist for life. Despite the often asymptomatic nature of the infection, *H. pylori* is a silent contributor to a spectrum of gastro-duodenal diseases that may progress to life-threatening conditions, including gastric cancer the third leading cause of cancer-related deaths worldwide (4).

The treatment of *H. pylori* infection is complex and continues to evolve. Historically, standard triple therapy comprising a proton pump inhibitor (PPI), clarithromycin, and amoxicillin or metronidazole was widely adopted as the first-line regimen. However, increasing antimicrobial resistance, particularly to clarithromycin and metronidazole, has significantly compromised the efficacy of this approach. In many regions, the eradication rate of triple therapy has dropped below the

***Corresponding Author:** **Dr. Arif A. Faruqui**, MD, MBBS Clinical Pharmacologist Department of Pharmacology 504-A, Rizvi Mahal CHS Opp. K. B. Bhabha Hospital Bandra West, Mumbai-400050 Maharashtra, India.. **Tel:** +91 9322426915, **Email:** drfaruqui@gmail.com.
Received: 02-July-2025, Manuscript No. JJOGASTRO - 4965 **; Editor Assigned:** 04-July-2025 **; Reviewed:** 08-August-2025, QC No. JJOGASTRO - 4965 **; Published:** 13-August-2025.
Citation: **Dr. Arif A. Faruqui**. Evaluating Rifaximin-Metronidazole Regimens for Helicobacter pylori Eradication: Current Evidence and Future Perspectives. Japanese Journal of Gastroenterology. 2025 August ; 12(1).

acceptable threshold of 80%, making it less reliable for first-line use (5,6).

The Maastricht VI/Florence Consensus Report and other international guidelines now recommend tailored therapy based on local antibiotic resistance patterns. Bismuth quadruple therapy (PPI, bismuth, tetracycline, and metronidazole) and non-bismuth concomitant or sequential therapies have gained prominence, especially in areas with high clarithromycin resistance. These regimens offer higher eradication rates but are often associated with increased side effects, complex dosing schedules, and lower patient compliance (7–10).

Fluoroquinolones are commonly used in rescue therapy after failure of initial *H. pylori* treatments; however, about 5–10% of patients still do not achieve eradication. For those who fail regimens involving clarithromycin, nitroimidazoles, fluoroquinolones, bismuth, tetracycline, or "three-in-one" combinations, empirical treatment options become limited. Rifabutin-based therapy has emerged as a promising alternative in such cases. *H. pylori* shows high in vitro susceptibility to rifabutin, a rifamycin S derivative with low resistance rates. Clinical studies have reported rifabutin resistance ranging from 0% to 46.1%, even among previously treated patients (11–13). The growing resistance to fluoroquinolones and rifabutin has significantly complicated their role in second-line and rescue therapies for *H. pylori* infection. This challenge is further amplified by rising antimicrobial resistance, frequent adverse events, and declining patient compliance all of which undermine the success of conventional treatment regimens. Consequently, there is an urgent need for alternative strategies that are not only effective and well-tolerated but also capable of overcoming resistance barriers, especially in patients with contraindications to standard therapies or those who have failed previous eradication efforts. These concerns have intensified the global search for novel therapeutic approaches that offer improved safety, efficacy, and resistance profiles.

In this context, rifaximin, a non-absorbable rifamycin derivative with a broad antimicrobial spectrum and a favorable safety profile (14), has emerged as a potential candidate. Its minimal systemic absorption and high intraluminal concentrations make it particularly suitable for gastrointestinal infections (15). When combined with metronidazole a well-known antibiotic with systemic action against anaerobic bacteria the resulting regimen may offer a synergistic advantage for *H. pylori* eradication. This review aims to evaluate the clinical potential of the rifaximin-metronidazole combination for *H. pylori* treatment. It discusses the pharmacological rationale, available clinical evidence, advantages over existing therapies, and future research directions necessary to validate its role in guideline-based management of *H. pylori* infection.

THE PROBLEM WITH STANDARD REGIMENS

Despite being the cornerstone of *H. pylori* eradication for decades, standard regimens particularly clarithromycin-based triple therapy are now increasingly ineffective due to the global rise in antimicrobial resistance. Once considered the gold standard, clarithromycin-containing triple therapy now achieves eradication rates as low as 60–75% in intention-to-treat (ITT) analyses in many parts of the world, particularly where clarithromycin resistance exceeds 15% (7,9). According to the Maastricht V/Florence Consensus Report, clarithromycin resistance has reached approximately 30% in Italy and Japan, 40% in Turkey, and up to 50% in China, while remaining lower in regions like Sweden and Taiwan (~15%) (9).

This alarming trend is not confined to isolated regions; it reflects a consistent global pattern of increasing antibiotic resistance across both high-income and low- to middle-income countries (16,17). Longitudinal surveillance studies from Europe, East Asia, and the Middle East have demonstrated a parallel rise in antibiotic resistance and decline in eradication success, reinforcing the urgent need for updated, region-specific strategies (18–20). Moreover, a recent Taiwanese study demonstrated an unintended consequence of antibiotic stewardship a notable rise in levofloxacin resistance following the restriction of macrolide use, highlighting the complexity of resistance dynamics and the importance of continuous surveillance and strategic policy design (21). Alternative regimens like bismuth quadruple therapy (BQT) which combines a PPI, bismuth, tetracycline, and metronidazole offer improved eradication rates of 85–95% in per-protocol (PP) analyses, even in areas with significant resistance. However, BQT is hindered by complex dosing schedules, increased gastrointestinal side effects, and lower patient adherence . Similarly, levofloxacin-based therapies, often used as second-line options, are increasingly compromised by rising fluoroquinolone resistance, <20% in several Asian and European regions (23). Meta-analyses consistently show that standard triple therapy fails to achieve the desired 90% eradication threshold in both ITT and PP populations, particularly in regions with high resistance. Moreover, adverse effects such as nausea, diarrhea, and taste disturbances commonly lead to treatment discontinuation, further impairing success rates (24–26).

Collectively, these challenges underline a critical therapeutic gap in *H. pylori* management. The limitations of standard regimens diminished efficacy, growing resistance, adverse effects, and poor compliance emphasize the pressing need for novel, simplified, and resistance-sparing treatment strategies. Future approaches should prioritize high efficacy, patient tolerability, and minimized resistance selection pressure, ideally informed by local susceptibility patterns or molecular resistance diagnostics.

RIFAXIMIN: PHARMACOLOGY AND MECHANISM

Rifaximin is a semi-synthetic, non-systemic antibiotic derived from rifamycin, primarily known for its role in treating gastrointestinal infections. Its primary mechanism of action involves inhibition of the beta-subunit of DNA-dependent RNA polymerase in bacterial cells, leading to suppression of RNA synthesis and cell death (27,28). What distinguishes rifaximin from other rifamycin derivatives is its negligible systemic absorption less than 0.4% after oral administration which ensures high concentrations within the gastrointestinal lumen while limiting systemic exposure and adverse effects (15). This pharmacokinetic profile allows rifaximin to exert a localized antibacterial effect, making it ideal for conditions such as hepatic encephalopathy, traveler's diarrhea, irritable bowel syndrome with diarrhea (IBS-D), and small intestinal bacterial overgrowth (SIBO). Importantly, this localization is also highly advantageous in the context of H. pylori, where bacterial colonization is restricted to the gastric mucosa (29).

Multiple studies have confirmed rifaximin's antibacterial spectrum, which includes both gram-positive and gram-negative organisms, aerobes, and anaerobes. Mégraud et al. (1994) evaluated rifaximin's in vitro activity against *H. pylori* isolates and reported MIC50 and MIC90 values of 4 µg/mL and 8 µg/mL, respectively comparable to commonly used agents like amoxicillin and bismuth salts (30). Notably, the activity of rifaximin remained stable in acidic pH, an essential attribute for drugs targeting gastric pathogens. However, Holton et al. (1995) also reported consistent rifaximin susceptibility among *H. pylori* isolates, reinforcing its potential as an anti-*H. pylori* agent (31). Furthermore, studies have shown that rifaximin retains efficacy against strains resistant to clarithromycin and metronidazole, suggesting a lack of cross-resistance mechanisms. Another important factor is the low risk of resistance development with rifaximin. Due to its poor systemic absorption, rifaximin exerts minimal pressure on extraintestinal flora, limiting the propagation of resistant strains. Resistance to rifaximin develops primarily via mutations in the rpoB gene (32); however, this is infrequently observed in clinical settings, particularly in short-course regimens (31,33,34).

In addition to its antibacterial action, rifaximin has demonstrated anti-inflammatory effects by modulating the gut microbiota and reducing mucosal inflammation (35), which could be beneficial in patients with gastritis or peptic ulcer disease coexisting with H. pylori infection.

Overall, rifaximin's pharmacokinetic and pharmacodynamic properties make it a compelling candidate for inclusion in *H. pylori* eradication regimens. Its combination of high intraluminal concentration, low systemic toxicity, broad-spectrum activity, and resistance profile provides a unique therapeutic advantage, especially when standard therapies are compromised by resistance or poor tolerability.

EVIDENCE OF RIFAXIMIN ACTIVITY AGAINST H. PYLORI

Multiple in vitro and clinical studies have evaluated the antimicrobial activity of rifaximin against *H. pylori*. One of the earliest and most cited studies, conducted by Mégraud et al. (1994), demonstrated that rifaximin exhibited MIC50 and MIC90 values of 4 µg/mL and 8 µg/mL, respectively, against clinical isolates of *H. pylori* (30). These MIC values are within the effective range observed for standard agents like amoxicillin and bismuth. Several studies have evaluated its inclusion in triple or quadruple regimens, especially as a rescue therapy. However, its overall clinical efficacy has not consistently met the desired eradication threshold of ≥90%, particularly in adult populations. However, Yun et al. (2012) tested it in a levofloxacin-based rescue regimen, rescue regimen combining rifaximin (200 mg TID), levofloxacin (500 mg QD), and a PPI over 7 days in 47 patients with multiple prior eradication failures. The eradication rate was 55.3% (ITT) and 65% (PP). Despite the modest eradication rate, the cumulative success across multiple regimens was 96%. However, thus rifaximin may serve as a rescue agent after failure of standard triple and quadruple therapies (36). Similarly, Choi et al. demonstrated that eradication regimens, the combination of omeprazole, amoxicillin, levofloxacin, and rifaximin (OAL-R) demonstrated eradication rates of 74.5% in the ITT population and 80.2% in the PP analysis. In contrast, the omeprazole, amoxicillin, clarithromycin (OAC) regimen achieved 77.8% (ITT) and 85.6% (PP), while the omeprazole, amoxicillin, levofloxacin (OAL) regimen showed lower rates of 65.3% (ITT) and 73.6% (PP), respectively (33). However, because of rifaximin's limited gastric mucosal penetration, studies such as Kim et al. and Ramas et al. showed only moderate eradication rates (67.5–75%), despite being part of quadruple regimens (37,38). Rifaximin has stronger intraluminal action and possibly reduced resistance in children, Nizhevich et al. reported an 85.4% eradication rate in pediatric patients, the highest among all included studies. This suggests rifaximin may be more effective in the pediatric population than in adults, possibly due to localized gastrointestinal targeting and different bacterial susceptibility profiles (39). Nevertheless, the largest systematic review by Wang et al. which included 12 studies (3 RCTs and 9 SATs), confirmed that rifaximin-containing regimens consistently failed to meet the minimum ideal eradication rate in adults. Because of high heterogeneity in study designs, populations, and resistance patterns, results varied widely (38.1% to 85.4%), with no significant improvement observed by modifying dose, duration, or combining with amoxicillin (40).

Overall, rifaximin demonstrates consistent in vitro activity and shows enhanced efficacy when used in combination with other agents. These findings highlight its potential as a component of alternative eradication regimens, particularly

in resistance-driven or compliance-challenged patient populations.

COMBINATION WITH METRONIDAZOLE: THE RATIONALE

Rifaximin and metronidazole operate through distinct but complementary mechanisms that enhance their potential as a combination therapy against H. pylori. Rifaximin acts locally within the gastrointestinal lumen by binding to the beta-subunit of bacterial DNA-dependent RNA polymerase, thereby inhibiting bacterial RNA synthesis. Due to its negligible systemic absorption, rifaximin remains highly concentrated in the gastrointestinal tract, directly targeting luminal and surface-associated *H. pylori* (27,28).

Metronidazole, on the other hand, is a nitroimidazole compound that is systemically absorbed and effective against anaerobic and microaerophilic bacteria, including H. pylori. Its mechanism involves the reduction of its nitro group by bacterial enzymes, leading to the production of reactive oxygen species that cause DNA strand breaks and cell death. Because of its excellent tissue penetration, metronidazole targets *H. pylori* that may reside deeper in the gastric mucosa (41,42). The combination of these two agents offers a dual mechanism rifaximin provides high local concentrations that suppress luminal bacterial populations, while metronidazole adds systemic coverage that may reach bacteria within deeper gastric niches. This complementary action may be particularly advantageous in treating infections with heterogeneous bacterial populations or biofilm-associated H. pylori.

In the study by Gasbarrini et al., various rifaximin-based regimens were evaluated for their efficacy in *H. pylori* eradication. Among these, the combination of rifaximin 400 mg BID with metronidazole 250 mg TID for 14 days achieved a notable 60% eradication rate, making it one of the more promising regimens in the context of dual therapy. This performance was comparable to the triple therapy of rifaximin + amoxicillin + omeprazole, which also showed a 60% eradication rate, despite issues related to formulation and patient compliance. Interestingly, the rifaximin + clarithromycin 500 mg BID combination achieved the highest eradication rate at 73%, while rifaximin alone yielded only 40%, and the rifaximin + bismuth (CBS) combination showed 50% success. In a later pilot study involving triple therapy, rifaximin + clarithromycin + esomeprazole (CRE) achieved a 58% eradication rate, while a similar regimen replacing clarithromycin with levofloxacin (LRE) showed a reduced rate of 42%.

Despite not achieving the ideal ≥90% target, the rifaximin + metronidazole regimen stands out as a simpler, two-drug combination with moderate efficacy, especially considering its tolerability and ease of administration (34). The dual mechanism rifaximin's gut-targeted broad-spectrum action and metronidazole's effectiveness in anaerobic conditions may account for the synergy observed. However, further research is needed to determine whether increasing duration, optimizing formulation (e.g., gastric-retentive delivery), or adding a proton pump inhibitor could enhance its performance. Among all regimens tested, rifaximin + metronidazole offers a balanced profile of efficacy, simplicity, and tolerability, and represents a potential candidate for further exploration in second-line or rescue therapy settings.

CLINICAL SCENARIOS FAVORING THIS COMBINATION

The rifaximin-metronidazole combination holds distinct value in several patient-specific and resistance-driven scenarios. In areas with high clarithromycin and fluoroquinolone resistance both of which significantly reduce the efficacy of standard regimens rifaximin offers a non-cross-resistant alternative with proven in vitro activity against resistant *H. pylori* strains (30,31). For patients allergic to penicillin, this combination avoids the use of beta-lactams entirely, thus filling a crucial treatment gap. Similarly, patients who cannot tolerate bismuth-based therapies due to gastrointestinal or neurological side effects (7,9) may benefit from the better-tolerated rifaximin-metronidazole regimen.

Comparative Evaluation (7,9,29,37,41,42)

Parameter	Standard Triple Therapy	Bismuth Quadruple Therapy	Rifaximin + Metronidazole (Proposed)
Resistance risk	High (Clarithromycin, Metronidazole)	Moderate (Metronidazole resistance only)	Low (Rifaximin has minimal resistance)
Systemic side effects	Moderate	High (GI upset, neurotoxicity)	Low (due to rifaximin's poor absorption)
Acid stability	Variable	Good	Good
Compliance	Variable	Poor (high pill burden)	Good
Clinical validation	Strong	Strong	Emerging; needs RCTs

LIMITATIONS AND RESEARCH GAPS

Despite the promising rationale and preliminary data supporting the rifaximin-metronidazole combination, there are notable limitations that hinder its current adoption in clinical guidelines. The most critical gap is the absence of large-scale, multicenter randomized controlled trials (RCTs). Most existing studies evaluating rifaximin in *H. pylori* treatment are small, open-label, or pilot in nature, limiting their statistical power and generalizability. Additionally, there is considerable variability in the design of published studies, particularly regarding the dosages, duration of therapy, and whether a proton pump inhibitor (PPI) or bismuth was co-administered. This heterogeneity makes it difficult to draw consistent conclusions about the efficacy of the regimen. Standardization of treatment protocols in future research is essential to validate the observed benefits.

Pharmacokinetic and pharmacodynamic data for rifaximin in the gastric environment are also limited. Given rifaximin's poor systemic absorption, its residence time in the stomach and its interaction with gastric mucus need further exploration to optimize dosage forms or delivery mechanisms. Furthermore, most available data focus on short-term outcomes without examining relapse rates, resistance development post-therapy, or long-term safety. There is a pressing need for studies that include follow-up beyond eradication confirmation, to assess durability and antimicrobial resistance trends. The role of rifaximin in specific patient subsets such as those with multiple prior treatment failures, comorbid gastrointestinal conditions, or high-risk populations remains inadequately explored. Research targeted at these niches could help position rifaximin-based regimens in real-world, personalized treatment pathways.

FUTURE PERSPECTIVES

The growing challenge of antimicrobial resistance in *H. pylori* treatment necessitates innovative strategies that go beyond traditional antibiotic regimens. Rifaximin, with its favorable pharmacokinetic profile and local action, emerges as a strong candidate for inclusion in future therapeutic protocols, especially when systemic side effects or resistance to systemic antibiotics pose significant barriers. Future clinical research should focus on large-scale, randomized controlled trials evaluating rifaximin in combination with metronidazole and other agents such as PPIs and bismuth. These studies must standardize dosage, treatment duration, and evaluation criteria to establish robust, generalizable data. In particular, trials comparing rifaximin-metronidazole regimens head-to-head with existing first-line therapies could help determine its relative efficacy and safety in real-world populations. Moreover, novel drug delivery strategies such as mucoadhesive, gastro-retentive formulations may enhance gastric mucosal contact time and increase drug efficacy. Pharmacokinetic and pharmacodynamic modeling will also be essential in optimizing the dosage to ensure therapeutic concentrations at the site of infection while minimizing the risk of resistance development.

Another avenue worth exploring is the use of rifaximin-based regimens in niche populations patients with prior treatment failure, those with antibiotic allergies (especially penicillin), the elderly, and those on polypharmacy regimens. Rifaximin's minimal systemic absorption and low interaction potential make it uniquely suited to these cases. Its dual benefit in comorbid gastrointestinal conditions, such as irritable bowel syndrome or small intestinal bacterial overgrowth, may further support its selection in patients with overlapping GI disorders. The rifaximin-metronidazole combination represents a promising frontier in *H. pylori* treatment. Its integration into clinical practice, however, depends on targeted research validating its efficacy, safety, and cost-effectiveness across diverse patient populations. With carefully designed studies and delivery innovations, this regimen could be positioned as a practical alternative or adjunct in resistance-driven or individualized therapy approaches.

CONCLUSION

Based on current evidence and scientific rationale, the combination of rifaximin and metronidazole holds meaningful potential as an alternative therapeutic strategy for H. pylori eradication, particularly in the context of rising antibiotic resistance and patient-specific contraindications to standard treatments. Unlike traditional regimens that are increasingly compromised by clarithromycin and fluoroquinolone resistance, rifaximin offers a non-cross-resistant mechanism, excellent gastrointestinal tolerability, and minimal systemic absorption, making it well-suited for localized infections such as H. pylori. In vitro studies have demonstrated rifaximin's consistent activity against H. pylori, including resistant strains. Clinical trials evaluating rifaximin-based regimens have reported moderate eradication rates (55.3–85.4%), with the rifaximin-metronidazole combination showing 60% success as a dual therapy. While falling short of the ideal 90% eradication rate, this combination shows promise in penicillin-allergic patients, those intolerant to bismuth or macrolides, and in salvage therapy after prior treatment failure. Its suitability in elderly populations and those with polypharmacy due to low drug-drug interaction potential adds further clinical value. However, the absence of large, multicentric, randomized controlled trials and standardized dosing protocols remains a major limitation. Further research is essential to confirm efficacy, optimize treatment regimens, and establish its role in first-line or tailored therapy. While rifaximin-metronidazole

is not yet ready to replace established regimens, its unique pharmacological benefits and preliminary success in pilot studies warrant its consideration for future therapeutic development and clinical trials. With further validation, it could serve as a reliable, patient-centric alternative in the expanding toolkit for H. pylori management. Furthermore, Its best outcomes have been noted in pediatric populations and select salvage regimens, but even these require further validation. Future research should focus on optimized delivery systems, such as floating or gastric-retentive formulations, to enhance mucosal contact and improve rifaximin's therapeutic potential.

REFERENCES

1. Ali A, AlHussaini KI. Helicobacter pylori: A Contemporary Perspective on Pathogenesis, Diagnosis and Treatment Strategies. Microorganisms. 2024 Jan;12(1):222.

2. Ahmed N. 23 years of the discovery of Helicobacter pylori: Is the debate over? Ann Clin Microbiol Antimicrob. 2005 Oct 31;4:17.

3. Yan L, He Q, Peng X, Lin S, Sha M, Zhao S, et al. Prevalence of Helicobacter pylori infection in the general population in Wuzhou, China: a cross-sectional study. Infect Agent Cancer. 2025 Jan 8;20(1):1.

4. Wroblewski LE, Peek RM, Wilson KT. Helicobacter pylori and Gastric Cancer: Factors That Modulate Disease Risk. Clin Microbiol Rev. 2010 Oct;23(4):713–39.

5. Graham DY, Dore MP, Lu H. Understanding treatment guidelines with bismuth and non-bismuth quadruple Helicobacter pylori eradication therapies. Expert Rev Anti Infect Ther. 2018 Sep;16(9):679–87.

6. Yang JC, Lu CW, Lin CJ. Treatment of Helicobacter pylori infection: Current status and future concepts. World J Gastroenterol WJG. 2014 May 14;20(18):5283–93.

7. Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2017 Feb;112(2):212–39.

8. Deane C, Kelly O, O'Morain C. Current and Future Perspectives on the Management of Helicobacter pylori: A Narrative Review. Antibiotics. 2024 Jun 10;13(6):541.

9. Malfertheiner P, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, et al. Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report. 2017 Jan 1 [cited 2025 Jun 16]; Available from: https://gut.bmj.com/content/66/1/6.long#block-system-main.

10. Ouyang Y, Zhang W, He C, Zhu Y, Lu N, Hu Y. Susceptibility-Guided Therapy vs. Bismuth-Containing Quadruple Therapy as the First-Line Treatment for Helicobacter pylori Infection: A Systematic Review and Meta-Analysis. Front Med. 2022 Mar 24;9:844915.

11. O'Connor A, Lamarque D, Gisbert JP, O'Morain C. Treatment of Helicobacter pylori infection 2017. Helicobacter. 2017 Sep;22 Suppl 1.

12. Pellicano R, Ribaldone DG, Fagoonee S, Astegiano M, Saracco GM, Mégraud F. A 2016 panorama of Helicobacter pylori infection: key messages for clinicians. Panminerva Med. 2016 Dec;58(4):304–17.

13. Ribaldone DG, Fagoonee S, Astegiano M, Durazzo M, Morgando A, Sprujevnik T, et al. Rifabutin-Based Rescue Therapy for Helicobacter pylori Eradication: A Long-Term Prospective Study in a Large Cohort of Difficult-to-Treat Patients. J Clin Med. 2019 Feb 6;8(2):199.

14. Hong KS, Kim JS. Rifaximin for the treatment of acute infectious diarrhea. Ther Adv Gastroenterol. 2011 Jul;4(4):227–35.

15. Koo HL, DuPont HL. Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases. Curr Opin Gastroenterol. 2010 Jan;26(1):17–25.

16. Antimicrobial resistance [Internet]. [cited 2025 Jun 17]. Available from: https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance.

17. Salam MdA, Al-Amin MdY, Salam MT, Pawar JS, Akhter N, Rabaan AA, et al. Antimicrobial Resistance: A Growing Serious Threat for Global Public Health. Healthcare. 2023 Jul 5;11(13):1946.

18. Chereau F, Opatowski L, Tourdjman M, Vong S. Risk assessment for antibiotic resistance in South East Asia. The BMJ. 2017 Sep 5;358:j3393.

19. Organization WH. Antimicrobial resistance surveillance in Europe 2023–2021 data. In: Antimicrobial resistance surveillance in Europe 2023–2021 data [Internet]. 2023 [cited 2025 Jun 17]. Available from: https://pesquisa.bvsalud.org/portal/resource/pt/who-366822.

20. Sihombing B, Bhatia R, Srivastava R, Aditama TY, Laxminarayan R, Rijal S. Response to antimicrobial resistance in South-East Asia Region. Lancet Reg Health - Southeast Asia [Internet]. 2023 Nov 1 [cited 2025 Jun 17];18. Available from: https://www.thelancet.com/journals/lansea/article/PIIS2772-3682%2823%2900166-X/fulltext.

21. Liou JM, Chang CY, Chen MJ, Chen CC, Fang YJ, Lee JY, et al. The Primary Resistance of Helicobacter pylori in Taiwan after the National Policy to Restrict Antibiotic Consumption and Its Relation to Virulence Factors-A Nationwide Study. PloS One. 2015;10(5):e0124199.

22. Sun Y, Zhu M, Yue L, Hu W. Multiple Bismuth Quadruple Therapy Containing Tetracyclines Combined with Other Antibiotics and Helicobacter pylori Eradication Therapy. J Clin Med. 2022 Nov 28;11(23):7040.

23. Papastergiou V, Georgopoulos SD, Karatapanis S. Treatment of Helicobacter pylori infection: Meeting the challenge of antimicrobial resistance. World J Gastroenterol WJG. 2014 Aug 7;20(29):9898–911.

24. Graham DY, Lu H, Yamaoka Y. A report card to grade Helicobacter pylori therapy. Helicobacter. 2007 Aug;12(4):275–8.

25. Graham DY, Shiotani A. New concepts of resistance in the treatment of Helicobacter pylori infections. Nat Clin Pract Gastroenterol Hepatol. 2008 Jun;5(6):321–31.

26. Urgesi R, Cianci R, Riccioni ME. Update on triple therapy for eradication of Helicobacter pylori: current status of the art. Clin Exp Gastroenterol. 2012 Sep 17;5:151–7.

27. DuPont HL. Review article: the antimicrobial effects of rifaximin on the gut microbiota. Aliment Pharmacol Ther. 2016 Jan;43 Suppl 1:3–10.

28. Scarpignato C, Pelosini I. Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. Chemotherapy. 2005;51 Suppl 1:36–66.

29. Robertson KD, Nagalli S. Rifaximin. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2025 Jun 17]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK562329/.

30. Mégraud F, Bouffant F, Camou Juncas C. In vitro activity of rifaximin against Helicobacter pylori. Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol. 1994 Feb;13(2):184–6.

31. Holton J, Vaira D, Menegatti M, Barbara L. The susceptibility of Helicobacter pylori to the rifamycin, rifaximin. J Antimicrob Chemother. 1995 Apr 1;35(4):545–9.

32. O'Connor JR, Galang MA, Sambol SP, Hecht DW, Vedantam G, Gerding DN, et al. Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile. Antimicrob Agents Chemother. 2008 Aug;52(8):2813–7.

33. Choi KH, Chung WC, Lee KM, Paik CN, Kim EJ, Kang BK, et al. Efficacy of Levofloxacin and Rifaximin based Quadruple Therapy in Helicobacter pylori Associated Gastroduodenal Disease: A Double-Blind, Randomized Controlled Trial. J Korean Med Sci. 2011 Jun 1;26(6):785–90.

34. Gasbarrini A, Gasbarrini G, Pelosini I, Scarpignato C. Eradication of Helicobacter pylori: Are Rifaximin-Based Regimens Effective? Digestion. 2006 Feb 27;73(Suppl. 1):129–35.

35. Gao J, Gillilland MG, Owyang C. Rifaximin, gut microbes and mucosal inflammation: unraveling a complex relationship. Gut Microbes. 2014 Jul 1;5(4):571–5.

36. Yun SP, Seon HG, Ok CS, Yoo KH, Kang MK, Kim WH, et al. Rifaximin Plus Levofloxacin-Based Rescue Regimen for the Eradication of Helicobacter pylori. 2012 Oct 29;6(4):452–6.

37. Kim HS, Yoon H, Shin DW, Oh DJ, Kwon M, Choi YJ, et al. Efficacy of and Resistance to Rifaximin-based Quadruple Therapy in Helicobacter pylori Eradication. Korean J Helicobacter Up Gastrointest Res. 2020 Sep 10;20(3):218–24.

38. Ramas M, Donday MG, McNicholl AG, Gisbert JP. Efficacy and safety of rifaximin associated with standard triple therapy (omeprazole, clarithromycin and amoxicillin) for H. pylori eradication: A phase IV pilot clinical trial. Gastroenterol Hepatol. 2017 Dec;40(10):658–62.

39. Nizhevich AA, Shcherbakov PL, Akhmadeeva ÉN, Khasanov RS. [Rifaximin in combined treatment of the Helicobacter pylori infection in childhood]. Eksp Klin Gastroenterol Exp Clin Gastroenterol. 2011;(1):85–7.

40. Wang Y, Tang J, Zhou S, Liang TT, Wang FF, Ning H. Effectiveness and Safety of Rifaximin-Containing Regimens for Helicobacter pylori Eradication: Systematic Review – Are They Potential Eradication Regimens? Infect Drug Resist. 2022 Jul 13;15:3733–49.

41. Huang Z, Zhu Y, Li X, Yao Z, Ge R. The mechanisms of metronidazole resistance of Helicobacter pylori: A transcriptomic and biochemical study. Microb Pathog. 2023 Oct 1;183:106303.

42. Weir CB, Le JK. Metronidazole. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2025 Jun 19]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK539728/.